Favipiravir (FAVI) and Remdesivir

DRUG-DRUG INTERACTIONS (DDIs)

**FAVIPIRAVIR**
- Prodrug conversion and antiviral action *may* be inhibited by acyclovir.
- Final metabolism *may* be inhibited by cimetidine, tamoxifen, calcium channel blockers, TCAs, and ondansetron
- FAVI *may* be a P450 inhibitor and affect diabetes drugs, loop diuretics, and buprenorphine

**REMDESIVIR**
- Inhibits viral replication, now in clinical trials in the US.
- In vivo metabolism appears to be chiefly by hydrolase activity, not P450 enzyme system
- Few, if any, verified reports of significant P450 DDIs involving remdesivir at this time

FAVI and remdesivir *do not have FDA approval*, so DDI information is incomplete, but DDIs for these drugs appear at present to be fewer than for alternative COVID-19 therapies – but clinicians must remain vigilant.

**NOTE:** FAVI diminishes acetaminophen metabolism (sulfonation), daily dose of acetaminophen MUST NOT exceed 3000 mg!